Association between Serum Osteocalcin and Markers of Metabolic Phenotype
Association between Serum Osteocalcin and Markers of Metabolic Phenotype
复制标题
DOI：
10.1210/jc.2008-1422
复制
发表时间：
2009-03-01
影响因子：
5.8
通讯作者：
Dawson-Hughes, Bess
中科院分区：
文献类型：
--
作者：
Pittas, Anastassios G.;Harris, Susan S.;Dawson-Hughes, Bess
内容：骨钙素参与调节实验动物的糖耐量、胰岛素分泌和敏感性。目的：我们的目的是使用来自65岁及以上成年人的已完成临床试验的数据来检查血清骨钙素浓度和代谢异常表型标志物之间的关系[n = 380，平均年龄71岁，体重指数（BMI）26.9 kg/m2，研究设计和方法：在横截面分析中，（基线数据），我们估计了血清骨钙素和尿N-端肽与代谢表型标志物（包括空腹血糖（FPG））的相关性。（主要结局）、空腹胰岛素、通过稳态模型评估胰岛素抵抗估计的胰岛素敏感性、血浆高敏C反应蛋白、IL-6，以及对潜在混杂因素进行多变量校正后的肥胖指标（BMI和体脂）（次要结局）。在前瞻性分析中（安慰剂组），我们估计了骨钙素和N-端肽与3年内主要结果FPG变化的关系。结果：在横断面分析中，血清骨钙素浓度与FPG呈负相关（P = 0.01），空腹胰岛素（P = 0.006），胰岛素抵抗的稳态模型评估（P = 0.002）、超敏C反应蛋白（P = 0.01）、IL-6（P = 0.02）、BMI（P <0.001）和体脂（P <0.001）。当参与者按血清骨钙素分为三分位时，骨钙素最高与最低三分位的平均FPG分别为97.1与104.8 mg/dl（P <0.01）。在前瞻性分析中，随访期间暴露于较高的骨钙素水平与3年时FPG的显著较低升高相关。尿N-端肽与代谢表型的任何标志物无关。结论：血清骨钙素浓度与代谢异常表型的血液标志物和肥胖的措施呈负相关。我们的研究结果应该被认为是假设生成，他们需要在人体研究中重复设计，以测试骨钙素影响代谢的假设。（临床内分泌代谢杂志94：827 - 832，2009）
Context: Osteocalcin has been reported to contribute to the regulation of glucose tolerance and insulin secretion and sensitivity in experimental animals.Objective: Our objective was to examine the association between serum osteocalcin concentration and markers of dysmetabolic phenotype using data from a completed clinical trial in adults age 65 and older [n = 380, mean age 71 yr, body mass index (BMI) 26.9 kg/m(2), 5% with diabetes].Research Design and Methods: In cross-sectional analyses (baseline data), we estimated the associations of serum osteocalcin and urine N-telopeptide with markers of metabolic phenotype including fasting plasma glucose (FPG) (primary outcome), fasting insulin, insulin sensitivity estimated by homeostasis model assessment for insulin resistance, plasma high-sensitivity C-reactive protein, IL-6, and measures of adiposity (BMI and body fat) (secondary outcomes) after multivariate adjustment for potential confounders. In prospective analysis (placebo arm), we estimated the associations of osteocalcin and N-telopeptide with change in the primary outcome, FPG, over a 3-yr period.Results: In cross-sectional analyses, serum osteocalcin concentration was inversely associated with FPG (P = 0.01), fasting insulin (P = 0.006), homeostasis model assessment for insulin resistance (P = 0.002), high-sensitivity C-reactive protein (P = 0.01), IL-6 (P = 0.02), BMI (P < 0.001), and body fat (P < 0.001). When participants were divided into tertiles by serum osteocalcin, mean FPG was 97.1 vs. 104.8 mg/dl in the highest vs. lowest osteocalcin tertile, respectively (P < 0.01). In prospective analyses, exposure to higher osteocalcin levels during follow-up was associated with a significantly lower rise in FPG at 3 yr. Urine N-telopeptide was not associated with any marker of metabolic phenotype.Conclusions: Serum osteocalcin concentration was inversely associated with blood markers of dysmetabolic phenotype and measures of adiposity. Our findings should be considered hypothesis generating, and they need to be replicated in human studies designed to test the hypothesis that osteocalcin affects metabolism. (J Clin Endocrinol Metab 94: 827-832, 2009)